Capricor's August 22 PDUFA Date Arrives With the Stock Up 97.39% on August 14 and a 3–9 Advisory Vote Hanging Over It

The most consequential binary event in small-cap biotech this week lands on Friday, August 22: the FDA's PDUFA decision on Capricor Therapeutics' (CAPR) deramiocel BLA for Duchenne muscular dystrophy cardiomyopathy.

The stock closed Friday, August 14 up 97.39% on the session, per Yahoo Finance data accessed August 16, 2026. Against a 52-week range of $2.96–$40.37, that single-day move tells the story of how sharply sentiment has swung heading into the deadline.

The path here was not clean. In late July, shares collapsed from around $19.70 on July 24 to $6.57 by July 29 after an FDA advisory committee voted 3–9 against evidence of effectiveness for cardiomyopathy in DMD — a lopsided result that would sink most BLA hopes. Volume on August 14 hit 65,341,079 shares, per Yahoo Finance data accessed August 16, 2026.

What kept the story alive was The Lancet. On July 29, 2026 — the same week the adcom voted — the journal published the Phase 3 HOPE-3 results. The trial met its primary endpoint, significantly slowing upper limb disease progression as measured by PUL 2.0 (p=0.029), with additional nominally significant functional and cardiac measures. The peer-reviewed data show deramiocel slowed upper-limb decline by 54% versus placebo in largely non-ambulatory DMD patients, with added cardiac benefits.

CEO Linda Marbán framed the regulatory moment this way in Capricor's March 10, 2026 press release announcing the Class 2 resubmission and new PDUFA date: "We believe the positive HOPE-3 results and broader clinical evidence reinforce Deramiocel's potential to become a first-in-class therapy for Duchenne muscular dystrophy, with the opportunity to address both skeletal and cardiac manifestations of the disease."

The FDA lifted its Complete Response Letter and resumed BLA review on March 10, 2026, per that same press release. The Class 2 resubmission carried the August 22 target action date.

On the analyst side, the adcom-driven selloff prompted two notable moves. Cantor Fitzgerald upgraded CAPR to Overweight and raised its price target to $28 from $3.50. Oppenheimer reiterated Outperform, citing strong risk-reward after a roughly 70% slide. Those are their forecasts, not this publication's.

Capricor's balance sheet, reported August 13, 2026 in its Q2 2026 earnings release, gives the company operational runway regardless of the outcome. Cash, cash equivalents, and marketable securities totaled approximately $237.9 million as of June 30, 2026, down from approximately $318.1 million as of December 31, 2025. Q2 2026 total operating expenses were $42.9 million versus $27.7 million a year earlier; net loss was $40.7 million, or $0.70 per share. The company recognized no revenue in the first half of 2026 or 2025.

One additional financial variable sits in the background: Capricor expects to be eligible to receive a Priority Review Voucher upon potential approval of deramiocel, per the company's disclosures.

The broader market sets a constructive backdrop for a risk event of this size. The S&P 500 recorded its 27th record high of 2026 on Thursday, August 14. The Russell 2000 hit all-time highs three times during the week ending August 15, gaining 1.1% on the week, per Trading Strategy Guides. The VIX fell to new 2026 lows below 14.4 and stood at 14.52 as of August 15, per Schwab's market update — about as calm an environment as a binary FDA decision could ask for.

What's next is straightforward: the FDA acts by August 22. The 3–9 adcom vote is the number investors are reconciling against the Lancet data between now and that date.